Nusinersen may be effective even if started later in children with SMA type 1 |
Journal Updates
eMediNexus Coverage from: 
Nusinersen may be effective even if started later in children with SMA type 1

0 Read Comments                

Nusinersen, which has been shown to be effective in the treatment of babies with the rare muscle-wasting disease spinal muscular atrophy type 1 may be effective for muscle control even when treatment is started in children seven months and older, according to a study published online August 29, 2018 in the journal Neurology. Six months after the injection, all 33 participants were alive and continuing treatment. Nusinersen was FDA-approved in December 2016 and is the first and only approved treatment for all types of SMA.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now